Piper Sandler reaffirms Buy on AbbVie stock: the price gains 1.69 percent

Published on 10/27/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The note dated October 26, 2026 names a USD 303.00 target. AbbVie stock costs EUR 258.70, 1.69 percent above the Xetra close.

Targets and earnings dates

Piper Sandler set a USD 303.00 target on October 26, 2026.
Second-quarter revenue reached USD 16.99 billion, up 10.20 percent year over year.
AbbVie stock trades at EUR 258.70 at 11:12 a.m. CET at Lang & Schwarz on October 27, 2026, 1.69 percent above the Xetra close of October 23, 2026.
Third-quarter results are scheduled for October 30, 2026.

AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) trades at EUR 258.70 at Lang & Schwarz on October 27, 2026 at 11:12 a.m. CET, 1.69 percent above the Xetra close of October 23, 2026 at EUR 254.40. Markets Insider reported on October 26, 2026 that Piper Sandler maintained a Buy rating and set a USD 303.00 price target.

Analyst support meets an earnings test

The target arrives before AbbVie's third-quarter report, making the October 30 release the next test for the valuation. AbbVie reported USD 16.99 billion in second-quarter revenue, up 10.20 percent from the same period a year earlier, while adjusted earnings per share reached USD 3.65. MarketBeat reported those second-quarter figures and the company guidance of USD 3.840-3.880 adjusted earnings per share for the third quarter.

What does the target mean for valuation?

The USD 303.00 target sits above the latest primary-market quote of USD 286.79 on October 26, 2026 at the NYSE, while the latest market capitalization was USD 506.8 billion. The same quote carried a 52-week range of USD 190.75 to USD 291.40, placing the primary-market price near its upper boundary. These figures frame the analyst call as an expectations test rather than a simple recovery trade.

Three dated AbbVie developments

On October 5, 2026, AbbVie disclosed a USD 216 million pre-tax acquired research and development charge and set third-quarter adjusted earnings-per-share guidance at USD 3.73-3.77 in an SEC filing. On October 22, 2026, Goldman Sachs raised its target from USD 258.00 to USD 294.00 while keeping a Neutral rating, according to Markets Insider. On October 26, 2026, Piper Sandler maintained its Buy rating and set the USD 303.00 target.

Dates for the next catalyst

AbbVie will announce third-quarter 2026 results on October 30, 2026, before the US market opens. The next dividend payment is scheduled for November 16, 2026, with the dividend set at USD 1.73 per share, according to MarketBeat.

AbbVie stock stays near its yearly high

The immediate question is whether the upcoming report can support the premium implied by the analyst targets and the stock's position near the USD 291.40 52-week high. AbbVie's second-quarter revenue growth of 10.20 percent offers a concrete benchmark for the next update. The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.